From 9 till 12 December 2023: HIGHLIGHTS FROM ASH

Your direct line with San Diego

From 9 till 12 December 2023, the 65th ASH (American Society of Hematology) Annual Meeting is taking place in San Diego, California. The MediMix team is onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen.

And, we also dive into posters and hot topics with both Belgian and international experts. Stay tuned!

With the educational support of:

Daily highlights

ASH 2023 Highlight 4

Two investigations provide novel insights into optimizing the therapeutic approach for patients with newly diagnosed multiple myeloma (NDMM) presenting high-risk features. High-risk categorization is contingent upon specific FISH abnormalities, such

See video »

ASH 2023 Highlight 3

We take pleasure in presenting the third daily highlight from the ASH 2023 event, featuring Evelien Krumb, a PhD candidate and medical trainee affiliated with Cliniques Universitaires Saint-Luc in Brussels.

See video »

ASH 2023 Highlight 2

Dr Rutger Callens, a haematologist at AZ Delta in Roeselare, graciously provided key insights into multiple myeloma. The IsKia EMN24 trial, presented in the plenary session, evaluated the efficacy and

See video »

ASH 2023 Highlight 1

The first daily highlight on ASH 2023 is done by Dr Bert Heyrman, haematologist at the ZNA Hospitals, Antwerp. He selected 4 presentations from the session on Myeloid Malignancies:

See video »

In-depth stories

ASH Highlights on Multiple Myeloma

Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from

See video »

Health related QoL data of KarMMa-3

KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care

See video »

Poster selection

The SKylaRK trial

Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received

See video »

Results from the Phase 1/2 Atalanta-1 trial

An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed

See video »

The REST study

Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway summarised the REST study.
In Norway, the use of VRd (bortezomib, lenalidomide and

See video »

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy